Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT06611852
Unknown Not applicable

Efficacy of Combined Interferential Therapy and Electronic Cupping Therapy for Chronic Constipation Management

NCT06611852 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2023-02-14
Last updated
2024-09-25

Condition(s) studied

Constipation

Investigational drug(s) / intervention(s)

Aerobic exerciseelectronic cupping therapy in addition to aerobic exerciseinterferential therapy in addition to aerobic exerciseinterferential therapy, electronic cupping therapy in addition to aerobic exercises

Aerobic exercise: Warm-up (5 minutes): Started with a 5-minute warm-up on the stationary bike at a low intensity to prepare the muscles for the workout. Interval Training (15 minutes): Alternated between 1 minute of high-intensity cycling (pedaling at a faster pace with higher resistance) and 2 minutes of moderate-intensity cycling (steady pace with moderate resistance). This interval was repeated for a total of 15 minutes. Hill Climbing (10 minutes): The resistance was increased on the stationary bike to simulate climbing a hill. Pedal at a slower pace but with higher resistance for 10 minutes to engage the muscles of legs and core. Cool Down (5 minutes): The stationary cycling session was finished with a 5-minute cool down at a low intensity to gradually lower the heart rate and avoid fatigue.

electronic cupping therapy in addition to aerobic exercise: Four devices of electronic cupping therapy were equipped with 3.5-inch diameter cups (Becommend, model number: BE007, ASIN: B09PVF72RJ, China).

interferential therapy in addition to aerobic exercise: interferential current (Endomed 482, SN/29.382, Netherlands) was delivered by the following parameters: a carrier frequency of 5-kHz, a beat frequency of 80-160 Hz, and an intensity level below 33 mA. Four carbon rubber electrodes (8x12 cm) were used and fixed by a large abdominal strap with a wet spongy

interferential therapy, electronic cupping therapy in addition to aerobic exercises: interferential therapy, electronic cupping therapy in addition to aerobic exercises

Study summary

Constipation is a common gastrointestinal issue affecting individuals worldwide. Interferential therapy, a form of electrotherapy, has been suggested to have potential benefits in improving gastrointestinal motility and relieving constipation symptoms. Introducing of a new method like electronic cupping therapy with interferential therapy may optimize the therapeutic outcomes by potentially increasing bowel movements and improving overall gastrointestinal function.

Eligibility

Sex
ALL
Min age
20 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * history of Chronic Constipation (CC), as defined by either experiencing two or fewer Complete Spontaneous Bowel Movements (CSBMs) per week for a minimum of 6 consecutive months before the screening visit * Reporting a sensation of incomplete evacuation or straining during at least a quarter of their bowel movements (according to the generally accepted definition of constipation). * Patients must have had CC persisting for more than 6 months, failed to respond to or be intolerant of medical treatment for at least 3 months Exclusion Criteria: * pregnant or lactating women * Chronic Constipation (CC) resulting from anorectal malformations such as colorectal or anal organic lesions, pelvic floor disorders requiring surgical intervention as determined by the investigator (such as rectal prolapse, rectocele, or enterocele) * presence of implanted electronic devices like cardiac pacemakers, defibrillators, cardiac pumps, or spinal stimulators * CC attributable to medications or neurologic, endocrine, or metabolic conditions * prior history of partial colectomy; conditions like megacolon, megarectum, or colonic inertia * skin abnormalities that hinder the placement of electrodes * women lacking adequate contraception (hormonal or intrauterine device).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
October 6 university October City Giza Governorate

More Middle East University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06611852 on ClinicalTrials.gov ↗ ← All trials in Egypt